XML 31 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Discontinued Operations (Details) (USD $)
Share data in Millions, unless otherwise specified
3 Months Ended 0 Months Ended 3 Months Ended 0 Months Ended
Mar. 31, 2015
Feb. 27, 2015
Feb. 10, 2015
Mar. 31, 2014
Feb. 27, 2015
Dec. 31, 2014
Proceeds from the disposition of business $ 230,000,000us-gaap_ProceedsFromDivestitureOfBusinesses          
After Tax Gain 1,737,000,000us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax          
Trade receivables, net 91,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet         498,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
Total inventories 54,000,000us-gaap_InventoriesPropertyHeldForSaleCurrent         254,000,000us-gaap_InventoriesPropertyHeldForSaleCurrent
Prepaid expenses, deferred income taxes, and other receivables 28,000,000abt_DisposalGroupIncludingDiscontinuedOperationPrepaidExpensesDeferredIncomeTaxesAndOtherCurrentReceivables         140,000,000abt_DisposalGroupIncludingDiscontinuedOperationPrepaidExpensesDeferredIncomeTaxesAndOtherCurrentReceivables
Current assets held for disposition 173,000,000us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent         892,000,000us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
Net property and equipment 2,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment         125,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
Intangible assets, net of amortization           804,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
Goodwill           950,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1
Deferred income taxes and other assets 1,000,000abt_DisposalGroupIncludingDiscontinuedOperationDeferredIncomeTaxesAndOtherAssets         55,000,000abt_DisposalGroupIncludingDiscontinuedOperationDeferredIncomeTaxesAndOtherAssets
Non-current assets held for disposition 3,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent         1,934,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
Total assets held for disposition 176,000,000us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation         2,826,000,000us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation
Trade accounts payable 286,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable         423,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable
Salaries, wages, commissions and other accrued liabilities 15,000,000abt_DisposalGroupIncludingDiscontinuedOperationsSalariesWagesCommissionsAndOtherAccruedLiabilities         257,000,000abt_DisposalGroupIncludingDiscontinuedOperationsSalariesWagesCommissionsAndOtherAccruedLiabilities
Current liabilities held for disposition 301,000,000us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent         680,000,000us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
Post-employment obligations, deferred income taxes and other long-term liabilities           108,000,000abt_DisposalGroupIncludingDiscontinuedOperationPostEmploymentBenefitObligationDeferredIncomeTaxesAndOtherLongTermLiabilities
Non-current liabilities held for disposition           108,000,000us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
Total liabilities held for disposition 301,000,000us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation         788,000,000us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
Developed markets branded generics pharmaceuticals business            
Amount of shares received for sale of generics pharmaceuticals business to Mylan Inc   5,770,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember
    5,770,000,000us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember
 
Period of notice require to terminate manufacturing supply of products 2 years          
After Tax Gain   1,600,000,000us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember
       
Developed markets branded generics pharmaceuticals business | Minimum            
Period for providing manufacturing supply of products 3 years          
Developed markets branded generics pharmaceuticals business | Maximum            
Period of transition services 2 years          
Period for providing manufacturing supply of products 10 years          
Animal Health Business            
Proceeds from the disposition of business     230,000,000us-gaap_ProceedsFromDivestitureOfBusinesses
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_AnimalHealthBusinessMember
     
After Tax Gain     131,000,000us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_AnimalHealthBusinessMember
     
AbbVie | Proprietary Pharmaceuticals Business Assets and Liabilities Held for Disposal            
Prepaid assets 164,000,000abt_DisposalGroupIncludingDiscontinuedOperationPrepaidAssets
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_ProprietaryPharmaceuticalProductsHeldForDisposalMember
/ dei_LegalEntityAxis
= us-gaap_SubsidiariesMember
         
AbbVie | Discontinued operations            
Earnings from discontinued operations, net tax benefits $ 13,000,000us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_ProprietaryPharmaceuticalProductsMember
/ dei_LegalEntityAxis
= us-gaap_SubsidiariesMember
    $ 36,000,000us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_ProprietaryPharmaceuticalProductsMember
/ dei_LegalEntityAxis
= us-gaap_SubsidiariesMember
   
Mylan | Developed markets branded generics pharmaceuticals business            
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc         110abt_ConsiderationReceivedForSaleOfBusinessInShares
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember
/ dei_LegalEntityAxis
= abt_MylanMember
 
Mylan NV | Developed markets branded generics pharmaceuticals business            
Percentage of shares received for sale of generics pharmaceuticals business to Mylan Inc   22.00%abt_ConsiderationReceivedForSaleOfBusinessInSharesAsPercentage
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember
/ dei_LegalEntityAxis
= abt_MyLanNVMember
    22.00%abt_ConsiderationReceivedForSaleOfBusinessInSharesAsPercentage
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= abt_DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember
/ dei_LegalEntityAxis
= abt_MyLanNVMember